Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Mantle cell lymphoma
ADR ID BADD_A05845
ADR Hierarchy
01      Blood and lymphatic system disorders
01.15      Lymphomas non-Hodgkin's B-cell
01.15.05      Mantle cell lymphomas
01.15.05.001      Mantle cell lymphoma
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.28      Lymphomas non-Hodgkin's B-cell
16.28.05      Mantle cell lymphomas
16.28.05.001      Mantle cell lymphoma
Description A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1). [MeSH]
MedDRA Code 10061275
MeSH ID D020522
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Centrocytic (mantle cell) lymphoma (Kiel classification) | Mantle cell lymphoma NOS | Mantle zone lymphoma | Small cleaved cell diffuse or nodular rarely diffuse mixed or large cleaved cell | Small cleaved follicular cell lymphoma (Mantle cell lymphoma) (Lukes-Collins Classification) | Mantle cell lymphoma | Lymphoma, Mantle-Cell | Lymphoma, Mantle Cell | Lymphomas, Mantle-Cell | Mantle-Cell Lymphomas | Lymphocytic Lymphoma, Diffuse, Poorly Differentiated | Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated | Mantle-Zone Lymphoma | Lymphoma, Mantle-Zone | Lymphomas, Mantle-Zone | Mantle Zone Lymphoma | Mantle-Zone Lymphomas | Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated | Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated | Lymphoma, Small-Cell, Centrocytic | Mantle-Cell Lymphoma | Mantle Cell Lymphoma | Diffuse Lymphocytic Lymphoma, Poorly-Differentiated | Diffuse Lymphocytic Lymphoma, Poorly Differentiated | Lymphoma, Centrocytic Small-Cell | Centrocytic Small-Cell Lymphoma | Centrocytic Small-Cell Lymphomas | Lymphoma, Centrocytic Small Cell | Lymphomas, Centrocytic Small-Cell | Small-Cell Lymphoma, Centrocytic | Small-Cell Lymphomas, Centrocytic | Lymphoma, Lymphocytic, Intermediate
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00230Bendamustine0.000246%
BADD_D00284Bortezomib0.000392%
BADD_D00612Desipramine0.007437%
BADD_D01119Ibrutinib0.004701%
BADD_D01130Idelalisib0.000112%
BADD_D01136Imatinib0.000112%
BADD_D01253Lenalidomide0.015504%
BADD_D02331Valsartan--
BADD_D02345Venetoclax0.001287%
BADD_D02464Fingolimod--
BADD_D02482Acalabrutinib0.000168%
BADD_D02487Baricitinib0.000241%
The 1th Page    1    Total 1 Pages